Possess valuable pharmacological activity. Particularly, the compounds are activators of GPR40 receptor and are therefore suitable for the treatment and Prevention of diseases which can be influenced by this receptor, such as Metabolic Diseases, including Type 2 diabetes.Claim 1: a compound characterized by the formula (1), in which R1 is selected from the group consisting of H, F, CL, BR, I, alkyl - 8 alquenilo C1, C2, C3, C2 alquinilo cycloalkyl - 6, - 12, - 12 cicloalquil C3 alkyl 4 bicicloalquil C1 - C5 -, 12 -, bicicloalquil C5 ALQ - 12 - UIL C1 - C5 - 6, cicloalquenilo - C5 - 6 - 6, cicloalquenil c1-4 alkyl, alquiloxi C1 - 8Cicloalquil C3 and C3 cicloalquil oxi - 6 - 4 - 6 - alquiloxi C1, where any of these groups is optional and independently replaced with 1 to 3 Fluorine Atoms and / or 1 to 3 groups heterociclilo C3 R4, - 12, - 12 heterociclil C3 alkyl c1-4 alkyl, bicicloheterociclil - bicicloheterociclil - C1 - 6 - het Erociclil c1-4 alkyl - Oxy - and heterocicliloxi C3 - 12Where any of these groups is optional and independently replaced with 1 to 3 groups R4, aryl, aryl alkyl c1-4 alkyl, aryl - C1 - 4 - Oxy, ariloxi, heteroaryl heteroaryl alkyl, c1-4 alkyl, heteroaryl - C1 - 4 - Oxy and heteroariloxi, where any of these groups is optional and Independent Entemente substituted with 1 to 5 groups R5, c1-4 alkyl - sulfanilo,- sulfinilo c1-4 alkyl and alkyl Sulfonyl - 4 - C1, where any of these groups is optionally substituted with 1 to 3 Fluorine ATOMS, and cyano, Nitro, amino, alquilamino c1-4 and di - (c1-4 alkyl) amino groups； and where subrestos heterociclilo mentioned above may be partially Unsaturated and comprise 1-3 hetero Atoms or groups or between selected NRN, N, and SUnder the condition that only two heteroatoms are o and S, and is not formed any link or - or S - s or - s or a methylene Group, while attached to an Atom can be replaced by a carbonyl Group, while the rest heterociclilo groups are attached to the respective through An atom of carbon
